(IDYA) IDEAYA Biosciences, Inc. SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(IDYA) IDEAYA Biosciences, Inc. Complete Analysis Pack
Make Confident Decisions Backed by Traceable Citations
This IDEAYA Biosciences, Inc. SWOT Analysis gives a concise, actionable view of the company’s strengths, weaknesses, opportunities, and threats for research, strategy, or investment decisions. The page already includes a real preview/sample of the analysis so you can evaluate style and substance before buying. Purchase the full version to receive the complete, ready-to-use SWOT report.
Strengths
Synthetic lethality oncology platform
IDEAYA Biosciences, Inc. is built around synthetic lethality, a precision oncology model that targets tumor-specific genetic flaws, so it stands apart from broad, non-biomarker drug developers. That focus gives it a clearer scientific edge and can create multiple programs from one biology engine, which supports more than one shot on goal. In 2025, that platform still anchors its pipeline strategy and long-term value creation.
Two lead clinical assets in development
IDEAYA Biosciences, Inc. has two visible clinical assets in human studies: IDE397 and IDE196. IDE397 is a Phase I MAT2A inhibitor for MTAP-deleted solid tumors, while IDE196 is a Phase I/II PKC inhibitor for GNAQ or GNA11-mutant cancers. Two active programs lower pipeline concentration risk and give the company multiple shots at clinical data readouts.
Biomarker-defined patient selection
IDEAYA Biosciences, Inc. builds its pipeline around biomarker-defined groups, including MTAP deletions, GNAQ or GNA11 mutations, BRCA or HRD alterations, and MSI-H, so target engagement is clearer and trial design is tighter. This focus supports smaller, faster studies and fits modern oncology’s move toward companion diagnostics and subgroup-based approvals.
Broad early-stage pipeline depth
IDEAYA Biosciences, Inc. has a broad early-stage pipeline beyond its lead assets, with PARG, Pol Theta, and WRN inhibitor programs that deepen its DNA damage and repair focus. That gives it at least 3 more shots at clinical value creation, not just 1 or 2 lead programs. In a field where only a fraction of oncology candidates reach approval, that spread lowers single-asset risk.
- 3 named early-stage programs
- More DNA repair targets
- More future value drivers
Strategic collaborations with major partners
IDEAYA Biosciences, Inc. has a strong edge from 3 external ties: a joint research effort with Cancer Research UK and the University of Manchester, plus 2 big pharma links with Pfizer and GSK. The Pfizer deal supports clinical development and supply in Phase I/II trials, which adds outside validation and lowers execution risk. The GSK alliance also broadens scientific reach and partner-backed credibility.
- 1 research tie with Cancer Research UK
- 1 university partner: Manchester
- 2 pharma partners: Pfizer and GSK
- Phase I/II support from Pfizer
IDEAYA’s Synthetic Lethality Edge Drives Precision Oncology Growth
IDEAYA Biosciences, Inc. stands out in synthetic lethality, giving it a focused precision oncology edge and a pipeline built from one core biology engine. In 2025, it had 2 clinical assets, 3 early-stage programs, and 2 big-pharma partners, which spreads risk and adds outside validation. Its biomarker-driven approach can also support smaller, faster trials.
| Strength | 2025 |
|---|---|
| Clinical assets | 2 |
| Early-stage programs | 3 |
| Pharma partners | 2 |
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing IDEAYA Biosciences, Inc.’s business strategy
Editable Excel File
Provides a quick SWOT snapshot for IDEAYA Biosciences to simplify strategic analysis and decision-making.
Reference Sources
Cites primary industry reports, SEC filings, clinical trial registries, and peer‑reviewed studies to fast-verify IDEAYA Biosciences' market, pricing, and competitive claims.
Weaknesses
No approved product revenue
IDEAYA Biosciences, Inc.’s lead assets remain investigational: IDE397 is in Phase I and IDE196 is in Phase I/II. The Company still has no approved or marketed oncology product, so product revenue is $0 and the business depends on future clinical success. That leaves valuation tied to trial readouts, FDA progress, and eventual approval.
Heavy reliance on early-stage assets
IDEAYA Biosciences, Inc. still leans on early-stage programs, with most pipeline value tied to preclinical work or Phase 1/2 assets and only a few programs near late-stage testing. That raises the odds of failure because early trials can miss on efficacy, safety, or timing. If one core asset slips, the impact can be outsized on valuation and sentiment.
Small number of lead programs
IDEAYA Biosciences, Inc. is still heavily tied to two lead assets, IDE397 and IDE196, so the near-term story depends on a narrow set of trial readouts. That concentration raises binary risk: one weak efficacy signal, safety issue, or delay can hit the stock hard. It also leaves IDEAYA Biosciences, Inc. far less diversified than larger oncology peers with many late-stage programs.
Biomarker-restricted addressable markets
IDEAYA Biosciences, Inc. relies on narrow biomarker-led markets: MTAP deletions occur in about 10%-15% of solid tumors, while GNAQ/GNA11 mutations cover most uveal melanoma cases. That precision can lift response rates, but it also shrinks the eligible pool and makes enrollment slower.
Smaller patient sets can also cap peak sales and raise launch risk, since each indication needs more testing, tighter diagnostics, and broader payer adoption to scale.
- MTAP-deleted tumors are a subset only.
- GNAQ/GNA11 targets are highly concentrated.
- Precision helps efficacy, hurts market size.
- Recruitment and commercialization get harder.
Partnership and execution dependence
IDEAYA Biosciences, Inc. depends on Pfizer, GSK, and academic partners for parts of its development network, so trial timing and priorities can shift outside its control. That creates coordination risk across programs and can slow decision making when partners move on different schedules.
- Partner timing can delay milestones.
- External control can limit execution.
- Priority shifts can slow programs.
For a biotech with a small internal base, even one delayed handoff can push data readouts, spending, and value creation. The weakness is not science alone, but shared control over key steps.
IDEAYA’s High-Stakes Pipeline Faces Narrow Markets and Early-Stage Risk
IDEAYA Biosciences, Inc. still has no approved drug, so revenue stays at $0 and the story depends on trial wins. Its pipeline is concentrated in a few early assets, which makes one weak readout or safety issue hit valuation fast. The addressable pools are also narrow: MTAP deletions are only about 10%-15% of solid tumors.
| Weakness | Data |
|---|---|
| No marketed product | Revenue: $0 |
| Lead assets early | Phase I to I/II |
| Narrow patient pool | MTAP: 10%-15% |
What You See Is What You Get
IDEAYA Biosciences, Inc. Reference Sources
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. It summarizes IDEAYA Biosciences’ strengths, weaknesses, opportunities, and threats with actionable insights for investors and strategists.
Opportunities
MTAP-deleted solid tumor expansion
IDE397 is being tested in MTAP-deleted solid tumors, and MTAP loss shows up in roughly 10% to 15% of all solid cancers. If IDEAYA Biosciences, Inc. confirms activity across tumor types, the program could expand from a single-trial set into a tumor-agnostic precision oncology franchise. That matters because one biomarker can open multiple cancers at once, not just one niche.
Uveal and skin melanoma growth
IDEAYA Biosciences, Inc.'s IDE196 targets GNAQ/GNA11-driven tumors, a mutation set found in about 90% of uveal melanoma cases and also in some skin melanoma subsets. Uveal melanoma is rare, with roughly 3,000 new U.S. cases a year, so strong data could open a bigger solid-tumor market. Skin melanoma adds scale, with about 100,000 U.S. cases a year, if the biology fits.
Advancing PARG, Pol Theta, and WRN into clinic
IDEAYA Biosciences, Inc.'s PARG, Pol Theta, and WRN inhibitor programs give it 3 shots on goal in distinct DNA repair and synthetic lethality pathways. Moving even 1 into clinic could add a new value driver and lower reliance on any single asset. That matters in a portfolio where pipeline breadth can support de-risking and long-term growth.
Diagnostic-driven precision medicine adoption
IDEAYA Biosciences, Inc. benefits as oncology shifts toward genomic testing; in 2025, the U.S. saw about 2.0 million new cancer cases, widening the pool for biomarker-led care. As next-generation sequencing becomes routine, matching patients to the right trial can cut screening waste and speed enrollment.
Biomarker testing supports cleaner trial entry.
Routine NGS can widen future addressable markets.
Faster enrollment can improve development efficiency.
Partner-enabled scale-up
Pfizer and GSK can widen IDEAYA Biosciences, Inc.'s trial reach, manufacturing support, and oncology know-how, so the company can move programs faster with less internal strain. Its work with Cancer Research UK and the University of Manchester also adds deep translational research access, which can improve target validation and trial design. In a capital-heavy field where late-stage oncology studies can run into tens of millions of dollars, partner scale-up can cut burn and speed data reads.
- Broader clinical and supply support
- More oncology expertise on tap
- Academic research depth and validation
- Lower internal load, faster development
IDEAYA’s Pipeline Targets Big, Biomarker-Driven Cancer Markets
IDEAYA Biosciences, Inc. has a clear upside from IDE397 in MTAP-deleted tumors, a biomarker seen in about 10% to 15% of solid cancers. IDE196 can also scale in GNAQ/GNA11 tumors, with GNAQ/GNA11 alterations in about 90% of uveal melanoma. A broader DNA-repair pipeline adds more shots on goal.
| Opportunity | Key data |
|---|---|
| IDE397 | 10% to 15% of solid cancers |
| IDE196 | About 90% uveal melanoma |
| Pipeline breadth | 3 preclinical programs |
Threats
Clinical trial failure risk
IDEAYA Biosciences, Inc.’s IDE397 and IDE196 are still early, so key efficacy and safety readouts are still ahead. Oncology is a high-fail field: only about 1 in 10 cancer drugs that enter Phase I reach approval, and many drop out in Phase II.
Any weak data could hit valuation fast, because these programs still carry most of their upside on future proof-of-concept results. Negative readouts can also slow partner interest and shrink momentum across the pipeline.
Competitive synthetic lethality landscape
IDEAYA Biosciences, Inc. faces a crowded synthetic lethality field, with many peers chasing DNA repair and biomarker-driven cancer drugs. In 2025, rivals with deeper data or faster trials can win key indications first, reducing IDEAYA Biosciences, Inc.'s edge. That raises the risk that best-in-class claims get harder to prove and commercial room gets tighter.
Regulatory and biomarker validation risk
IDEAYA Biosciences, Inc. is exposed to regulatory and biomarker validation risk because its pipeline depends on tight molecular selection: MTAP deletion, GNAQ/GNA11 mutations, BRCA/HRD status, and MSI-H. MTAP loss appears in about 10% to 15% of cancers, while MSI-H is only a small subset, so regulators may demand strong companion diagnostic and clinical proof before broad use. If these biomarkers are not fully validated, trial enrollment can slow and development timelines can slip.
Safety, resistance, and combination challenges
IDEAYA's biggest threat is that targeted oncology drugs can hit the right biology and still fail on safety, resistance, or short response time. That risk is sharper in first-in-class synthetic lethality programs, where only a few tumors may respond and resistance can emerge fast.
Combination therapy can help, but it also raises trial size, cost, and safety risk; IDEAYA had more than $900 million in cash and investments in 2025, so it can fund this work, but longer and more complex development still pressures timelines.
For investors, the key issue is durability: if response rates stay narrow or resistance shows up early, even strong science may not turn into durable revenue.
- On-target toxicity can limit dosing
- Resistance can cut response durability
- Combinations add cost and risk
- Early programs face higher failure odds
Funding and partner concentration pressure
Founded in 2015, IDEAYA Biosciences, Inc. is still a development-stage biotech, so it must keep funding trials and pipeline work before any product sales. That makes it sensitive to tighter capital markets, and even a short delay in financing can push back timelines. Dependence on a few large partners also raises risk if those partners shift priorities.
- Needs steady outside funding
- Slow capital access can delay trials
- Few partners raise concentration risk
IDEAYA Faces High Early-Stage Clinical and Competitive Risk
IDEAYA Biosciences, Inc. faces high clinical failure risk, since early oncology programs like IDE397 and IDE196 still need proof of efficacy and safety. Competition in synthetic lethality is tight, so slower data can let rivals win key targets first. Biomarker dependence and regulatory proof needs can also slow enrollment and approvals.
| Threat | Why it matters |
|---|---|
| Early-stage trials | Most Phase I cancer drugs fail |
| Competitive pressure | Peers may reach market first |
| Biomarker risk | Validation can delay trials |
| Funding need | 2025 cash and investments topped $900M |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.